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NTDs affect over 1 billion people, and cause 170,000 deaths each year. They result in disability,
stigma and disfigurement. NTDs also push families into poverty—the direct financial costs of
illness due to visceral leishmaniasis exceed 20% of total annual household expenditure for 30%
of households in Ethiopia, around a quarter of households in Bangladesh and Sudan, and 14%
of households in India. These figures are stark, but there is important progress. In the past five
years, the number of people at risk for NTDs fell by 20 percent–from 2 billion to 1.6 billion.
Some countries are now able to stop mass drug administration for some NTDs. These are
amazing achievements. Particularly in this, the 5th anniversary of the London Declaration on
NTDs, we need to celebrate these successes, and also collectively step up, to tackle remaining
and new challenges.
Motivated by the need to tackle the impacts that NTDs have on the poor in the developing
world, the UK has had a long history of NTD support, using its funding and influence to
champion and help catalyse the academic, public and private sector to take action. As NTDs
primarily occur in rural and poor urban areas of low-income and middle-income countries
[1], NTDs not only provides an important marker for global progress towards achieving uni-
versal access to health, but also towards the leave no-one behind agenda, and the commitment
that development should seek to improve the lives of the poorest and most vulnerable in the
world.
Strong partnership has been central to the achievements to date. Effective partnership with
endemic countries has been critical. Partnership with other donors, pharmaceutical compa-
nies, multilateral organisations such as WHO and the World Bank, and a wide range of organi-
sations that provide support and technical assistance to NTD programmes on the ground,
have also been central to successes to date. The UK and the USA have been the largest bilateral
donors on NTD implementation, with the Bill and Melinda Gates Foundation also providing
substantial support. The UK made a commitment to spend an additional £195m at the London
Declaration on NTDs. Working in partnership with national governments, the UK supports
programmes to tackle a range of NTDs. These include delivering over 136m treatments for the
diseases tackled through mass drug administration in 2016; reducing disability by supporting
surgery for hydrocoeles due to lymphatic filariasis and surgery to prevent blindness from tra-
choma. Funding has helped support Asia achieve elimination of visceral leishmaniasis as a
public health problem; and supported African countries with visceral leishmaniasis to achieve
better control, including the earlier detection and response of outbreaks. Support to the Carter
Center has contributed to the eradication of Guinea worm disease: in 2016 there were 25 cases
of GWD in only 3 countries down from over 3m a year in more than 20 countries when the
programme started in 1986.
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Our ability to tackle NTDs has been greatly enhanced by the availability of highly cost effec-
tive treatment options. Most people requiring a package of essential NTD medicines can be
reached by mass treatment for less than US$0.50 per person. This includes treatment for schis-
tosomiasis, trachoma, lymphatic filariasis, onchocerciasis and soil transmitted helminths.
Most drugs have been donated by the pharmaceutical industry. Without this generous support,
announced at the London Declaration, and valued at US$17.8 million to 2020, we would not
have achieved the progress seen to date.
Looking forward, we need to look for opportunities to achieve synergies in programming.
The seven preventive chemotherapy diseases (ascariasis, hookworm infections, lymphatic fila-
riasis, onchocerciasis, schistosomiasis, trichuriasis, and trachoma) are preventable by a simple
oral drug treatment, administered once or twice a year. Due to the geographic overlap of
endemic areas for some NTDs, and a common requirement for preventive chemotherapy, an
integrated approach to mass drug administration has been increasingly adopted. This inte-
grated approach provides a means to make cost savings and increase efficiency compared to
single disease approaches. We need to learn from and accelerate this approach, and identify
what adaptations may be required as progress continues to be made. There are other areas also
where integrated action can lead to multiple impacts. Improving access to clean water, hygiene
and sanitation will help prevent trachoma and schistosomiasis, but will also have wider health
benefits. The WHO Water, Sanitation and Hygiene strategy for accelerating and sustaining
progress on NTDs is important, but we still need to learn the best ways to implement this.
Rigorous research and new innovation remains an important part of the NTD response.
DFID supported NTD research includes both product development and operational research.
This has resulted in new drugs for sleeping sickness, visceral leishmaniasis, Chagas disease and
diagnostics for sleeping sickness through the work of Drugs for Neglected Diseases Initiative
(DNDi) and Foundation for Innovative New Diagnostics respectively. DFID is also investing
in development of new insecticides through Innovative Vector Control Consortium and
implementation research on the integrated approach to mass drug administration for tackling
NTDs through COUNTDOWN.
Progress will only continue to be made by being innovative, testing new technologies and
approaches to programming, and assessing how established approaches may need to be
adapted to respond to different epidemiological and geographic contexts. It is critical that new
research findings–both positive and negative–are disseminated promptly, so that lessons can
be learnt about what forms of intervention are effective, and those that are not.
Strong surveillance and monitoring will continue to form an important backbone of NTD
programmes. As we make progress we need to modify and test new approaches to mapping
and surveillance in low prevalence settings. New digital technologies may provide opportuni-
ties to do things differently, more rapidly, and more efficiently moving forward. We also need
rigorous data on the impact of programmes on disease transmission and health burden, to
help make the case for further investment. Though knowing we have delivered millions of
treatments is important; information on reductions in prevalence or intensity of infections is
vital. Similarly, we need to know whether countries are meeting the criteria to stop Mass drug
administration either nationally or in some geographic areas. Rigorous cost effectiveness data
will continue also to be important, to ensure that available resources are used for the greatest
possible good.
With the successes to date, the NTD field will need to respond to the new epidemiological
and contextual realities. The world’s populations are becoming increasingly urbanised, yet
many established models of intervention have been tested and used in rural populations. For
example, public school systems often provide an important platform for preventive therapy for
schistosomiasis. We need to ensure that children in informal or private schools, and children
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who are not attending school, are getting the same access to preventive chemotherapy. We
need to identify also how best to deliver effective interventions in challenging and complex set-
tings–such as within fragile and conflict affected states, and to migrant and displaced popula-
tions. It is in these settings where many of the most vulnerable live, and where the burden of
NTDs will increasingly be concentrated.
There has been much progress since the London Declaration. Yet NTD transmission con-
tinues in many countries, and hundreds of millions of people still do not have access to the
treatments that they need. We cannot be complacent. If we are to achieve global targets we
must continue to work in strong partnership, and rise to tackle new challenges. The research
community will continue to have an essential role to play–generating and testing the new tools
and rigorous evidence needed to ensure that the burden of NTDs can continue to be reduced,
and that no-one is left behind.
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